Medifast (NYSE:MED) Posts Earnings Results, Beats Expectations By $0.36 EPS

Medifast (NYSE:MED) posted its earnings results on Monday. The specialty retailer reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.36, FiscalAI reports. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.The company had revenue of $76.04 million for the quarter, compared to the consensus estimate of $69.20 million. Medifast updated its FY 2026 guidance to -2.750–1.550 EPS and its Q2 2026 guidance to -1.000–0.500 EPS.

Medifast Trading Down 3.0%

NYSE:MED traded down $0.33 during trading hours on Monday, reaching $10.58. 149,536 shares of the company were exchanged, compared to its average volume of 241,665. The firm has a market cap of $116.76 million, a PE ratio of -6.19 and a beta of 0.55. The stock’s 50-day moving average is $10.41 and its 200-day moving average is $11.10. Medifast has a twelve month low of $9.22 and a twelve month high of $15.46.

Insider Activity at Medifast

In related news, CEO Daniel R. Chard bought 17,678 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was acquired at an average price of $10.11 per share, with a total value of $178,724.58. Following the completion of the purchase, the chief executive officer directly owned 17,678 shares of the company’s stock, valued at approximately $178,724.58. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 3.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Medifast

Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock valued at $32,000 after purchasing an additional 1,187 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Medifast during the third quarter worth $37,000. Intesa Sanpaolo Wealth Management purchased a new stake in shares of Medifast during the fourth quarter worth $47,000. State of Wyoming purchased a new stake in shares of Medifast during the fourth quarter worth $59,000. Finally, Strs Ohio purchased a new stake in shares of Medifast in the 1st quarter valued at approximately $78,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MED has been the topic of a number of analyst reports. Wall Street Zen raised Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Stephens dropped their target price on Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Medifast in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $12.00.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.